Similar to the effect of IL-6 treatment on HCC in the SBR50 group, all animals in the SBR35/IL-6 group were successfully resuscitated compared to 80% of rats in the placebo-treated SBR35 group (data not shown). This evidence concerns the gene IL6 and hepatocellular carcinoma.